| 1 | Also referred to as 'MEDI2070'Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 240-Product Name: BrazikumabProduct Code: MEDI2070Pharmaceutical Form: Solution for injection/infusionINN or Proposed INN: BRAZIKUMABCAS Number: 1610353-18-8Other descriptive name: Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody | - | - | - | - | [1] 97 97 💬
|
| 2 | BRAZIKUMAB | [1] Brazikumab Brazikumab (Brazikumab) | [1] Brazikumab
Brazikumab
(Brazikumab) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [2] 96 96, 97 💬
|
| 3 | Brazikumab high dose | [1] Brazikumab Brazikumab (Brazikumab) | [1] Brazikumab
Brazikumab
(Brazikumab) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
| 4 | Brazikumab Induction Dose | [1] Brazikumab Brazikumab (Brazikumab) | [1] Brazikumab
Brazikumab
(Brazikumab) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [2] 96 96, 97 💬
|
| 5 | Brazikumab IV Infusion | [1] Brazikumab Brazikumab (Brazikumab) | [1] Brazikumab
Brazikumab
(Brazikumab) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
| 6 | Brazikumab low dose | [1] Brazikumab Brazikumab (Brazikumab) | [1] Brazikumab
Brazikumab
(Brazikumab) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
| 7 | Brazikumab Maintenance Dose | [1] Brazikumab Brazikumab (Brazikumab) | [1] Brazikumab
Brazikumab
(Brazikumab) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [2] 96 96, 97 💬
|
| 8 | Brazikumab SC Injection | [1] Brazikumab Brazikumab (Brazikumab) | [1] Brazikumab
Brazikumab
(Brazikumab) 💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
| 9 | BrazikumabProduct Code: MEDI2070Pharmaceutical Form: Solution for injection/infusion in pre-filled syringeINN or Proposed INN: BRAZIKUMABCAS Number: 1610353-18-8Other descriptive name: Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody | - | - | - | - | [1] 97 97 💬
|